INCY - Incyte Corporation
NEXT EARNINGS:
May 5, 2026
EPS Est: $1.40
|
Rev Est: $1.2B
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$108.90
DETAILS
HIGH:
$135.00
LOW:
$84.00
MEDIAN:
$108.50
CONSENSUS:
$108.90
UPSIDE:
20.60%
Market Cap:
17.97B
Volume:
1,488,122
Avg Volume:
1,873,828
52 Week Range:
53.56-112.29
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.84
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
2,617
IPO Date:
1993-11-04
EPS (TTM):
6.60
P/E Ratio:
13.68
Revenue (TTM):
5.14B
Total Assets:
6.96B
Total Debt:
69.43M
Cash & Equiv:
3.10B
Rev Growth (5Y):
14.0%
EPS Growth (5Y):
31.8%
FCF Growth (5Y):
24.8%
ROCE:
30.6%
Debt/Equity:
0.01
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-10 | $1.80 | $1.90 | -5.3% | $1.5B | $1.4B | +11.2% |
| 2025-10-28 | $2.26 | $1.66 | +36.1% | $1.4B | $1.4B | +0.9% |
| 2025-07-29 | $1.57 | $1.39 | +12.9% | $1.2B | $1.3B | -3.3% |
| 2025-04-29 | $1.16 | $1.01 | +14.9% | $1.1B | $1.2B | -8.7% |
| 2025-02-10 | $1.43 | $1.57 | -8.9% | $1.2B | $1.0B | +17.3% |
| 2024-10-29 | $1.07 | $1.12 | -4.5% | $1.1B | $1.1B | -0.5% |
| 2024-07-30 | $-1.82 | $0.78 | -333.3% | $1.0B | $1.0B | +1.8% |
| 2024-04-30 | $0.64 | $0.84 | -23.8% | $880.9M | $921.9M | -4.4% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.14B | 4.24B | 3.70B | 3.39B | 2.99B | 2.67B | 2.16B | 1.88B | 1.54B | 1.11B | 753.75M | 511.50M |
| Net Income | 1.29B | 32.62M | 597.60M | 340.66M | 948.58M | (295.70M) | 446.91M | 109.49M | (313.14M) | 104.22M | 6.53M | (48.48M) |
| EPS | 6.59 | 0.16 | 2.67 | 1.53 | 4.30 | -1.36 | 2.08 | 0.52 | -1.53 | 0.55 | 0.04 | -0.29 |
| Total Assets | 6.96B | 5.44B | 6.78B | 5.84B | 4.93B | 3.56B | 3.43B | 2.65B | 2.30B | 1.64B | 1.01B | 830.07M |
| Total Debt | 69.43M | 43.54M | 38.29M | 41.46M | 44.82M | 47.53M | 60.23M | 36.13M | 24.00M | 651.48M | 619.89M | 675.17M |
| Cash & Equivalents | 3.10B | 1.69B | 3.21B | 2.95B | 2.06B | 1.51B | 1.83B | 1.16B | 899.51M | 652.34M | 521.44M | 452.30M |
| Operating Cash Flow | 1.41B | 335.34M | 496.49M | 969.94M | 749.49M | (124.60M) | 710.66M | 336.23M | (92.99M) | 304.76M | 86.54M | 26.26M |
| Free Cash Flow | 1.35B | 249.07M | 449.00M | 892.11M | 568.48M | (311.98M) | 632.59M | 262.74M | (204.01M) | 184.48M | 60.53M | (1.62M) |
| FCF per Share | 6.94 | 1.20 | 2.01 | 4.02 | 2.58 | -1.43 | 2.94 | 1.24 | -1.00 | 0.98 | 0.34 | -0.01 |
| Book Value | 5.17B | 3.45B | 5.19B | 4.37B | 3.77B | 2.61B | 2.60B | 1.93B | 1.63B | 419.47M | 171.16M | (81.63M) |
| Cash & ST Investments | 3.58B | 2.16B | 3.66B | 3.24B | 2.35B | 1.80B | 2.12B | 1.44B | 1.17B | 808.55M | 707.78M | 600.26M |
| ROC Equity | 0.25 | 0.01 | 0.12 | 0.08 | 0.25 | -0.11 | 0.17 | 0.06 | -0.19 | 0.25 | 0.04 | N/A |